Lineage Cell Therapeutics
LCTX
132 hedge funds and large institutions have $153M invested in Lineage Cell Therapeutics in 2026 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 25 increasing their positions, 29 reducing their positions, and 32 closing their positions.
413% more call options, than puts
Call options by funds: $154K | Put options by funds: $30K
13% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 32
1.91% more ownership
Funds ownership: 44.84% → 46.75% (+1.9%)
2% more funds holding
Funds holding: 130 → 132 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less capital invested
Capital invested by funds: $176M → $153M (-$23.2M)
14% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.9M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.84M |
| 3 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$1.76M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.69M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$5.03M |
| 2 |
Millennium Management
New York
|
-$3.51M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.46M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.72M |
| 5 |
Jane Street
New York
|
-$1.3M |
LCTX Hedge Fund Activity: Q2 2026 in Review
132 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2026, worth a combined $153M — down 13% from $176M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new LCTX positions and 32 closed out — a net gain of 4 holders — while 25 added to existing stakes and 29 trimmed.
The largest buyer was BlackRock, adding an estimated $12.9M. The largest seller was Armistice Capital, exiting entirely with an estimated $5.03M sold.
- 132 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2026, up from 130 in Q1 2026.
- Funds reported $153M of Lineage Cell Therapeutics stock for Q2 2026, down 13% quarter-over-quarter.
- 36 funds opened new Lineage Cell Therapeutics positions in Q2 2026 and 32 closed out, a net change of +4 holders.
- The largest Lineage Cell Therapeutics buyer in Q2 2026 was BlackRock, an estimated $12.9M added.
- The largest Lineage Cell Therapeutics seller in Q2 2026 was Armistice Capital, an estimated $5.03M sold.
Based on aggregated 13F filings for Q2 2026.